ImmunityBio, Inc.
Clinical trials sponsored by ImmunityBio, Inc., explained in plain language.
Immunotherapy biotech developing cancer treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immune booster plus standard therapy shows promise for bladder cancer Results expected Sep 2026 (estimated)
- Could an immune booster beat long COVID? small trial begins Results expected Oct 2026 (estimated)
- New bladder cancer cocktail aims to spare patients from surgery Results expected Nov 2026 (estimated)
- Immune cell cocktail takes on Platinum-Resistant ovarian cancer Results expected May 2027 (estimated)
- New immune-boosting combo targets stubborn lymphoma Results expected May 2027 (estimated)
-
Can a drug rev up the immune system to fight sepsis?
Disease control Not yet recruitingThis trial is testing whether adding an immune-stimulating drug called nogapendekin alfa inbakicept (NAI) to standard intensive care can help adults with sepsis or septic shock. Participants receive NAI as an injection under the skin on the first day, with possible additional dos…
Phase 1/2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New Vaccine-Drug combo aims to tame HPV throat cancer with less radiation
Disease control Not yet recruitingThis study tests a new treatment plan for people with HPV-positive oropharyngeal cancer (a type of throat cancer linked to HPV). The plan combines an immune-boosting drug (nogapendekin alfa inbakicept), a vaccine targeting HPV, chemotherapy, and a lower dose of radiation. The goa…
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can a new drug help sepsis patients with weak immune systems?
Disease control Not yet recruitingThis Phase 2 trial tests whether adding the drug nogapendekin alfa inbakicept (NAI) to standard sepsis care can improve survival in critically ill adults with sepsis and persistently low lymphocyte counts (a sign of immune suppression). About 50 participants will be randomly assi…
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New immune combo aims to fight lymphoma without chemo
Disease control Not yet recruitingThis study tests a new drug combination for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The treatment uses three immune-based drugs (CD19 t-haNK, NAI, and rituximab) without chemotherapy. About 20 adults …
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New bladder cancer cocktail aims to spare patients from surgery
Disease control Not yet recruitingThis phase 2 trial tests whether a drug called N-803, combined with either BCG or gemcitabine, can treat intermediate-risk bladder cancer without needing surgery. About 20 adults with low-grade papillary tumors will receive the drugs directly into the bladder. The main goal is to…
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC